NCT02340676View on ClinicalTrials.gov

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2025

Conditions
Chronic Graft-versus-host-disease
Interventions
PROCEDURE

Extracorporeal Photopheresis (ECP)

Participants receive ECP treatment twice a week for 16 weeks

DRUG

Interleukin-2

Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16

Trial Locations (1)

02215

Dana-Farber Cancer Insitute, Boston

Sponsors

Collaborators (1)

Prometheus Laboratories
All Listed Sponsors
collaborator

Prometheus Laboratories

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER